CapVest seeks to move Curium into a large CV-on-CV

The buyout firm moved Curium Pharma into a €1.2bn single-asset continuation fund in 2020.

SECONDARIES INVESTOR

Register to unlock this content

• Daily global secondaries market news and intelligence
• Curated insights to keep you ahead of GP-led and LP-led secondaries
• Faster, data-driven decision making powered by our AI interface, 'Ask PEI'
• Access to proprietary research and reports
• Selected fund performance and investor activity data

Register nowFind out more

DealsWestern EuropeSecondariesSingle AssetsFeaturedGP-Leds